About Tyrosine-protein phosphatase non-receptor type 7
Tyrosine-protein phosphatase non-receptor type 7 (PTPN7) is a protein
from Homo sapiens identified by UniProt accession
P35236, 360 residues long.
MolForge cross-references it against 0 known binders and
48 disease associations.
Target properties
| Protein name | Tyrosine-protein phosphatase non-receptor type 7 |
| UniProt accession | P35236 |
| Gene | PTPN7 |
| Organism | Homo sapiens |
| Length | 360 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (48)
Diseases linked to this target (Open Targets).
- basophil percentage of leukocytes · score 0.34
- platelet crit · score 0.33
- neurodegenerative disease · score 0.30
- heel bone mineral density · score 0.27
- body mass index · score 0.26
- platelet count · score 0.20
- mean platelet volume · score 0.16
- inflammatory bowel disease · score 0.13
- mean corpuscular volume · score 0.08
- neoplasm · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P35236-F1 | alphafold | PREDICTED | 85.76 | — |
Amino-acid sequence (360 residues)
MVQAHGGRSR AQPLTLSLGA AMTQPPPEKT PAKKHVRLQE RRGSNVALML DVRSLGAVEP ICSVNTPREV TLHFLRTAGH PLTRWALQRQ PPSPKQLEEE FLKIPSNFVS PEDLDIPGHA SKDRYKTILP NPQSRVCLGR AQSQEDGDYI NANYIRGYDG KEKVYIATQG PMPNTVSDFW EMVWQEEVSL IVMLTQLREG KEKCVHYWPT EEETYGPFQI RIQDMKECPE YTVRQLTIQY QEERRSVKHI LFSAWPDHQT PESAGPLLRL VAEVEESPET AAHPGPIVVH CSAGIGRTGC FIATRIGCQQ LKARGEVDIL GIVCQLRLDR GGMIQTAEQY QFLHHTLALY AGQLPEEPSP
Explore Tyrosine-protein phosphatase non-receptor type 7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets